From trial volumes to published research output and regulatory milestones, here is a data-driven assessment of where China stands in the global stem cell research landscape.
China's emergence as a global leader in stem cell medicine is often discussed in qualitative terms. This article focuses on the data: publications, clinical trial volumes, regulatory milestones, investment figures, and comparative metrics that allow an objective assessment of China's standing.
China's Stem Cell Research in Context
China's emergence as a global leader in stem cell medicine is often discussed in qualitative terms. This article focuses on the data: publications, clinical trial volumes, regulatory milestones, investment figures, and comparative metrics that allow an objective assessment of China's standing.
Clinical Trial Volume: A Clear Leader
The most definitive measure of clinical research scale is registered clinical trial volume. According to a comprehensive analysis published in Journal of Hematology & Oncology (October 2024):
- China registered 2,794 total cell therapy clinical trials between 2005 and 2024
- CAR-T trials: 46.9% of all immune cell therapy trials (816 registered)
- MSC trials: 847 registered — more than any other country
- 2024 growth rate: 42% increase in new CDE registrations vs. 2023
- For CAR-T specifically: China now registers more trials than the United States
By comparison, the US ClinicalTrials.gov database lists approximately 1,200 active stem cell trials of all types as of early 2025. While direct comparison requires methodological care, the aggregate numbers confirm China's scale.
Research Publication Output
China's stem cell research publication output has grown dramatically:
- Annual peer-reviewed publications with Chinese lead author affiliation: ~8,400 in 2024 (up from ~2,100 in 2015 — a 4x increase in a decade)
- Share of global stem cell publications: China accounts for approximately 28% of global stem cell research output by volume
- High-impact publications: Chinese institutions appear in Nature, Cell Stem Cell, Science, and NEJM with increasing frequency — though US institutions still lead in high-impact journal share
Publication volume alone does not equal research quality — this is an important caveat. However, the trajectory, combined with regulatory milestones, suggests that China's stem cell research is not only high-volume but increasingly rigorous.
Key Research Institutions
China's stem cell research is concentrated in a network of elite institutions:
- Chinese Academy of Sciences (CAS) — Institute of Zoology (Beijing): Pioneer in iPSC (induced pluripotent stem cell) research; published landmark work on chemical reprogramming of human somatic cells
- Peking University: Leading iPSC and organoid research programs; multiple Nature-level publications
- Tsinghua University: Hematopoietic stem cell biology and CAR-T engineering
- Chinese Academy of Medical Sciences: Blood diseases and hematopoietic stem cell transplantation — one of the world's highest-volume allogeneic HSCT programs
- Nanjing Drum Tower Hospital: World's largest MSC transplantation program for autoimmune disease
- Shanghai Jiao Tong University Medical School: Broad stem cell research across multiple disease areas
Regulatory Milestones: Increasing Maturity
China's cell therapy regulatory milestones tell a story of rapid development:
- 2015: First stem cell-specific regulatory framework (NHC hospital-based research classification)
- 2017: First CAR-T products entering Phase II trials under CDE oversight
- 2021: Axicabtagene ciloleucel (axi-cel) approved — first CAR-T commercial approval in China
- 2022: Mandatory IND filing requirement for all cell therapy trials (NMPA Announcement No. 8)
- 2023: Relmacabtagene autoleucel (relma-cel) approved — first China-developed CAR-T product
- 2025: Amimestrocel (Ruibosheng) approved — first MSC drug approval globally for aGVHD
The 2025 MSC approval is particularly significant: it represents the world's first fully regulated commercial MSC therapy, establishing a precedent that could influence regulatory pathways in the US and EU where MSC products remain in the trials phase.
Investment and Industry Scale
- Government investment in cell therapy R&D: Estimated USD 2+ billion since 2010 through the National Key R&D Programs and major national science funds
- Number of NMPA-certified GMP cell manufacturing facilities: 100+ as of 2024
- Number of registered cell therapy biobanks: Over 60
- Cord blood banking: China operates the world's largest network of public cord blood banks (7 NMPA-licensed banks, storing millions of units)
Where China Lags
An honest assessment acknowledges areas where China's stem cell ecosystem remains behind global leaders:
- Gene editing integration: US institutions lead in clinical applications of CRISPR-based gene editing combined with cell therapy
- iPSC clinical translation: Japan leads in clinical iPSC-derived therapy (retinal cells, cardiac patches); China's iPSC clinical program lags despite strong basic research
- Long-term follow-up data: China's trial boom is relatively recent; 5-year and 10-year outcomes data is limited for most indications
- International peer review: High publication volume, but some concern about reproducibility in lower-impact journals
The Takeaway for International Patients
China's stem cell ecosystem in 2025 is the largest in the world by trial volume, has achieved regulatory milestones no other country has matched (first commercial MSC approval), and is producing increasingly rigorous clinical evidence. For patients with specific conditions and documented eligibility, engaging with China's academic medical centers offers access to therapies simply not available elsewhere — at a fraction of comparable costs in Western markets.
Sources: Journal of Hematology & Oncology October 2024 (PMC11476068); Web of Science publication database 2024; NMPA official announcements; BioInformant Global Cell Therapy Industry Report 2025.